AstraZeneca turns down option on Astellas' diabetes programs
This article was originally published in Scrip
Executive Summary
AstraZeneca is not exercising its option to acquire the Phase II and preclinical assets, PSN821 and PSN842 respectively, from Astellas Pharma for the treatment of type 2 diabetes.